Last reviewed · How we verify
Insulin Degludec / Liraglutide Injectable Product
Insulin Degludec / Liraglutide Injectable Product is a Insulin/GLP-1 receptor agonist combination Small molecule drug developed by University of Palermo. It is currently FDA-approved for Type 2 diabetes mellitus. Also known as: Insulin Degludec/Liraglutide.
This combination product uses insulin degludec to provide long-acting basal insulin coverage and liraglutide to stimulate GLP-1 receptors, enhancing insulin secretion and reducing appetite for improved glycemic control.
This combination product uses insulin degludec to provide long-acting basal insulin coverage and liraglutide to stimulate GLP-1 receptors, enhancing insulin secretion and reducing appetite for improved glycemic control. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Insulin Degludec / Liraglutide Injectable Product |
|---|---|
| Also known as | Insulin Degludec/Liraglutide |
| Sponsor | University of Palermo |
| Drug class | Insulin/GLP-1 receptor agonist combination |
| Target | Insulin receptor; GLP-1 receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin degludec is an ultra-long-acting basal insulin analog that provides steady glucose control over 24+ hours. Liraglutide is a GLP-1 receptor agonist that stimulates insulin secretion in response to meals, slows gastric emptying, and promotes satiety. Together, they address both fasting and postprandial glucose levels while supporting weight loss.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Hypoglycemia
- Injection site reactions
- Headache
Key clinical trials
- A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects (PHASE1)
- Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients (PHASE4)
- Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin Degludec / Liraglutide Injectable Product CI brief — competitive landscape report
- Insulin Degludec / Liraglutide Injectable Product updates RSS · CI watch RSS
- University of Palermo portfolio CI
Frequently asked questions about Insulin Degludec / Liraglutide Injectable Product
What is Insulin Degludec / Liraglutide Injectable Product?
How does Insulin Degludec / Liraglutide Injectable Product work?
What is Insulin Degludec / Liraglutide Injectable Product used for?
Who makes Insulin Degludec / Liraglutide Injectable Product?
Is Insulin Degludec / Liraglutide Injectable Product also known as anything else?
What drug class is Insulin Degludec / Liraglutide Injectable Product in?
What development phase is Insulin Degludec / Liraglutide Injectable Product in?
What are the side effects of Insulin Degludec / Liraglutide Injectable Product?
What does Insulin Degludec / Liraglutide Injectable Product target?
Related
- Drug class: All Insulin/GLP-1 receptor agonist combination drugs
- Target: All drugs targeting Insulin receptor; GLP-1 receptor
- Manufacturer: University of Palermo — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
- Also known as: Insulin Degludec/Liraglutide
- Compare: Insulin Degludec / Liraglutide Injectable Product vs similar drugs
- Pricing: Insulin Degludec / Liraglutide Injectable Product cost, discount & access